CN102083834A - 用于治疗丙型肝炎的7H-吲哚并[2，1-a][2]苯并氮杂*-10-羧酸衍生物 - Google Patents
用于治疗丙型肝炎的7H-吲哚并[2，1-a][2]苯并氮杂*-10-羧酸衍生物 Download PDFInfo
- Publication number
- CN102083834A CN102083834A CN2009801263266A CN200980126326A CN102083834A CN 102083834 A CN102083834 A CN 102083834A CN 2009801263266 A CN2009801263266 A CN 2009801263266A CN 200980126326 A CN200980126326 A CN 200980126326A CN 102083834 A CN102083834 A CN 102083834A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- solvent
- mmol
- carbonyl
- cyclohexyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 *N(CCC12CN(*)CCC1)C2=O Chemical compound *N(CCC12CN(*)CCC1)C2=O 0.000 description 5
- SJRJJKPEHAURKC-UHFFFAOYSA-N CN1CCOCC1 Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- OXLOUMASMYPWND-UHFFFAOYSA-N C(C1)C2NC3C12OC3 Chemical compound C(C1)C2NC3C12OC3 OXLOUMASMYPWND-UHFFFAOYSA-N 0.000 description 1
- FTPNQECUSUQJTD-UHFFFAOYSA-N C1C2(C3)OCC13NC2 Chemical compound C1C2(C3)OCC13NC2 FTPNQECUSUQJTD-UHFFFAOYSA-N 0.000 description 1
- MESXDUGNXBNUFT-OBJUSKSNSA-N CC(C)/C(/C(N1C[C@@H](COC)OCC1)=O)=C(/C(C[n]1c2c3)=Cc(cc(cc4)OC)c4-c1c(C1CCCCC1)c2ccc3C(NS(C(C)C)(=O)=O)=O)\N(C1CCC1)N Chemical compound CC(C)/C(/C(N1C[C@@H](COC)OCC1)=O)=C(/C(C[n]1c2c3)=Cc(cc(cc4)OC)c4-c1c(C1CCCCC1)c2ccc3C(NS(C(C)C)(=O)=O)=O)\N(C1CCC1)N MESXDUGNXBNUFT-OBJUSKSNSA-N 0.000 description 1
- DMZXYWAYGVYUDX-UHFFFAOYSA-N CC(C)CS(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCC4)nc4)c4C(N4C5CN(C)CC4CC5)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)CS(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCC4)nc4)c4C(N4C5CN(C)CC4CC5)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O DMZXYWAYGVYUDX-UHFFFAOYSA-N 0.000 description 1
- RWDHAOSEPUMIAD-UHFFFAOYSA-N CC(C)CS(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCOCC4)nc4)c4C(N4CC(CC5)N(C)C5C4)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)CS(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCOCC4)nc4)c4C(N4CC(CC5)N(C)C5C4)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O RWDHAOSEPUMIAD-UHFFFAOYSA-N 0.000 description 1
- ADLZBZVKNVUMOI-UHFFFAOYSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](-c4c(C)cncc4)nc4)c4C(N(C(CC4)C5)C4CC5(C)O)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](-c4c(C)cncc4)nc4)c4C(N(C(CC4)C5)C4CC5(C)O)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O ADLZBZVKNVUMOI-UHFFFAOYSA-N 0.000 description 1
- PWNWVAUAHSMKFM-UHFFFAOYSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCC4)nc4)c4C(N(CCC4)C5C4OC5)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCC4)nc4)c4C(N(CCC4)C5C4OC5)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O PWNWVAUAHSMKFM-UHFFFAOYSA-N 0.000 description 1
- FKCUEFRPLBTAJB-CDZUIXILSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCC4)nc4)c4C(N4[C@@H](C5)CO[C@@H]5C4)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCC4)nc4)c4C(N4[C@@H](C5)CO[C@@H]5C4)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O FKCUEFRPLBTAJB-CDZUIXILSA-N 0.000 description 1
- LYRRTARGACIANK-UHFFFAOYSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCC4)nc4)c4C(O)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCC4)nc4)c4C(O)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O LYRRTARGACIANK-UHFFFAOYSA-N 0.000 description 1
- FAGRKXCBHHLQDU-HNRBIFIRSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCOCC4)nc4)c4C(N4C[C@H](C)O[C@H](C)C4)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCOCC4)nc4)c4C(N4C[C@H](C)O[C@H](C)C4)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O FAGRKXCBHHLQDU-HNRBIFIRSA-N 0.000 description 1
- LBMUXOFUUHMERM-UHFFFAOYSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCOCC4)nc4)c4C(O)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCOCC4)nc4)c4C(O)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O LBMUXOFUUHMERM-UHFFFAOYSA-N 0.000 description 1
- PNHQKARQANCHAV-MKPDMIMOSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c4c(C(N5C[C@H](C)O[C@H](C)C5)=O)c(C)n[n]4C4CCC4)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c4c(C(N5C[C@H](C)O[C@H](C)C5)=O)c(C)n[n]4C4CCC4)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O PNHQKARQANCHAV-MKPDMIMOSA-N 0.000 description 1
- HDCAVCCESZODFP-UHFFFAOYSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c4c(C(O)=O)c(C)n[n]4C4CCC4)=Cc4c-2ccc(OC)c4)c3c1)=O)(=C)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c4c(C(O)=O)c(C)n[n]4C4CCC4)=Cc4c-2ccc(OC)c4)c3c1)=O)(=C)=O HDCAVCCESZODFP-UHFFFAOYSA-N 0.000 description 1
- USXPUFDBCXAXIG-UHFFFAOYSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c4c(C(O)=O)c(C)n[n]4C4CCC4)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c4c(C(O)=O)c(C)n[n]4C4CCC4)=Cc4c-2ccc(OC)c4)c3c1)=O)(=O)=O USXPUFDBCXAXIG-UHFFFAOYSA-N 0.000 description 1
- YKWKXJRWKUHGOV-UHFFFAOYSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c2[n]3CC(c([n](C4CCC4)nc4)c4C(O)=O)=CC(C4)=C2C=CC4OC)c3c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c2[n]3CC(c([n](C4CCC4)nc4)c4C(O)=O)=CC(C4)=C2C=CC4OC)c3c1)=O)(=O)=O YKWKXJRWKUHGOV-UHFFFAOYSA-N 0.000 description 1
- CUTLAVULSMYGDR-UHFFFAOYSA-N CCc(cc1)cc(C=C(C[n]2c3c4)c5c(C(O)=O)c(C)n[n]5C5CCC5)c1-c2c(C1CCCCC1)c3ccc4C(NS(C(C)C)(=O)=O)=O Chemical compound CCc(cc1)cc(C=C(C[n]2c3c4)c5c(C(O)=O)c(C)n[n]5C5CCC5)c1-c2c(C1CCCCC1)c3ccc4C(NS(C(C)C)(=O)=O)=O CUTLAVULSMYGDR-UHFFFAOYSA-N 0.000 description 1
- QOYMAVPMWWLKTB-UHFFFAOYSA-N CN(C)/S=[O]/CNC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCC4)nc4)c4C(N4C5CN(C)CC4CC5)=O)=Cc4c-2ccc(OC)c4)c3c1)=O Chemical compound CN(C)/S=[O]/CNC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCC4)nc4)c4C(N4C5CN(C)CC4CC5)=O)=Cc4c-2ccc(OC)c4)c3c1)=O QOYMAVPMWWLKTB-UHFFFAOYSA-N 0.000 description 1
- ADZZFDNDACYCDI-UHFFFAOYSA-N CN(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCC4)nc4)c4C(O)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=C)=O Chemical compound CN(C)S(NC(c1ccc(c(C2CCCCC2)c-2[n]3CC(c([n](C4CCC4)nc4)c4C(O)=O)=Cc4c-2ccc(OC)c4)c3c1)=O)(=C)=O ADZZFDNDACYCDI-UHFFFAOYSA-N 0.000 description 1
- ZPELJYYPPKJKBE-LURJTMIESA-N COC[C@H]1OCCNC1 Chemical compound COC[C@H]1OCCNC1 ZPELJYYPPKJKBE-LURJTMIESA-N 0.000 description 1
- HNVIQLPOGUDBSU-OLQVQODUSA-N C[C@H]1O[C@@H](C)CNC1 Chemical compound C[C@H]1O[C@@H](C)CNC1 HNVIQLPOGUDBSU-OLQVQODUSA-N 0.000 description 1
- NBUPNBSZAFMAAB-UHFFFAOYSA-N NC(C1C=CC=C2)C12N Chemical compound NC(C1C=CC=C2)C12N NBUPNBSZAFMAAB-UHFFFAOYSA-N 0.000 description 1
- GEYOCULIXLDCMW-UHFFFAOYSA-N Nc1ccccc1N Chemical compound Nc1ccccc1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5074308P | 2008-05-06 | 2008-05-06 | |
| US61/050,743 | 2008-05-06 | ||
| PCT/US2009/042805 WO2009137454A1 (en) | 2008-05-06 | 2009-05-05 | 7h-indolo[2,1-a] [2] benzazepine-10-carboxylic acid derivatives for the treatment of hepatitis c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102083834A true CN102083834A (zh) | 2011-06-01 |
Family
ID=40786514
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009801263266A Pending CN102083834A (zh) | 2008-05-06 | 2009-05-05 | 用于治疗丙型肝炎的7H-吲哚并[2，1-a][2]苯并氮杂*-10-羧酸衍生物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8133884B2 (https=) |
| EP (1) | EP2280975B1 (https=) |
| JP (1) | JP2011520810A (https=) |
| KR (1) | KR20110015588A (https=) |
| CN (1) | CN102083834A (https=) |
| AR (1) | AR071684A1 (https=) |
| AU (1) | AU2009244409A1 (https=) |
| BR (1) | BRPI0915130A2 (https=) |
| CA (1) | CA2723683A1 (https=) |
| CL (1) | CL2009001089A1 (https=) |
| CO (1) | CO6290645A2 (https=) |
| EA (1) | EA201001748A1 (https=) |
| IL (1) | IL208753A0 (https=) |
| MX (1) | MX2010011921A (https=) |
| NZ (1) | NZ588556A (https=) |
| PE (1) | PE20091879A1 (https=) |
| TW (1) | TW200951135A (https=) |
| WO (1) | WO2009137454A1 (https=) |
| ZA (1) | ZA201007649B (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070049593A1 (en) | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| KR20100124848A (ko) | 2008-03-27 | 2010-11-29 | 브리스톨-마이어스 스큅 컴퍼니 | 방향족 헤테로시클릭 융합된 인돌로벤자디아제핀 ｈｃｖ ｎｓ5ｂ 억제제 |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| CA2822357A1 (en) | 2010-12-22 | 2012-06-28 | Abbvie Inc. | Hepatitis c inhibitors and uses thereof |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| CA2862755A1 (en) | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| EP3091022A3 (en) * | 2012-07-18 | 2016-12-14 | Bristol-Myers Squibb Holdings Ireland | Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007092888A2 (en) * | 2006-02-08 | 2007-08-16 | Bristol-Myers Squibb Company | Hcv ns5b inhibitors |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20090250T1 (hr) | 2004-02-24 | 2009-06-30 | Japan Tobacco | Kondenzirani heterociklički spojevi i njihova upotreba kao inhibitora hcv polimeraze |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| EP1807403A2 (en) | 2004-10-26 | 2007-07-18 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Tetracyclic indole derivatives as antiviral agents |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7399758B2 (en) | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| GB0608928D0 (en) | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7456166B2 (en) | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| WO2007140200A2 (en) | 2006-05-25 | 2007-12-06 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
| JP5205370B2 (ja) | 2006-05-25 | 2013-06-05 | ブリストル−マイヤーズ スクイブ カンパニー | シクロプロピル縮合インドロベンゾアゼピンｈｃｖｎｓ５ｂ阻害剤 |
| US7452876B2 (en) | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7541351B2 (en) | 2007-01-11 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7517872B2 (en) | 2007-02-22 | 2009-04-14 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7538102B2 (en) | 2007-03-14 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7521444B2 (en) | 2007-03-14 | 2009-04-21 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7541353B2 (en) | 2007-03-14 | 2009-06-02 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7547690B2 (en) | 2007-03-14 | 2009-06-16 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US7538103B2 (en) | 2007-03-15 | 2009-05-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US20090018163A1 (en) | 2007-07-11 | 2009-01-15 | Bristol-Myers Squibb Company | Substituted Heterocyclic Ethers and Their Use in CNS Disorders |
| US7642251B2 (en) | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7652004B2 (en) | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8124601B2 (en) | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US8129367B2 (en) | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
-
2009
- 2009-05-04 US US12/434,748 patent/US8133884B2/en active Active
- 2009-05-05 CA CA2723683A patent/CA2723683A1/en not_active Abandoned
- 2009-05-05 PE PE2009000605A patent/PE20091879A1/es not_active Application Discontinuation
- 2009-05-05 EP EP09743440.1A patent/EP2280975B1/en not_active Ceased
- 2009-05-05 AU AU2009244409A patent/AU2009244409A1/en not_active Abandoned
- 2009-05-05 CN CN2009801263266A patent/CN102083834A/zh active Pending
- 2009-05-05 NZ NZ588556A patent/NZ588556A/en not_active IP Right Cessation
- 2009-05-05 KR KR1020107027222A patent/KR20110015588A/ko not_active Withdrawn
- 2009-05-05 WO PCT/US2009/042805 patent/WO2009137454A1/en not_active Ceased
- 2009-05-05 BR BRPI0915130A patent/BRPI0915130A2/pt not_active IP Right Cessation
- 2009-05-05 EA EA201001748A patent/EA201001748A1/ru unknown
- 2009-05-05 JP JP2011508593A patent/JP2011520810A/ja not_active Withdrawn
- 2009-05-05 MX MX2010011921A patent/MX2010011921A/es active IP Right Grant
- 2009-05-06 TW TW098115001A patent/TW200951135A/zh unknown
- 2009-05-06 AR ARP090101641A patent/AR071684A1/es not_active Application Discontinuation
- 2009-05-06 CL CL2009001089A patent/CL2009001089A1/es unknown
-
2010
- 2010-10-14 IL IL208753A patent/IL208753A0/en unknown
- 2010-10-26 ZA ZA2010/07649A patent/ZA201007649B/en unknown
- 2010-10-28 CO CO10134256A patent/CO6290645A2/es not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007092888A2 (en) * | 2006-02-08 | 2007-08-16 | Bristol-Myers Squibb Company | Hcv ns5b inhibitors |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2280975A1 (en) | 2011-02-09 |
| PE20091879A1 (es) | 2009-12-19 |
| CL2009001089A1 (es) | 2011-04-29 |
| US20090280083A1 (en) | 2009-11-12 |
| CO6290645A2 (es) | 2011-06-20 |
| US8133884B2 (en) | 2012-03-13 |
| JP2011520810A (ja) | 2011-07-21 |
| CA2723683A1 (en) | 2009-11-12 |
| BRPI0915130A2 (pt) | 2019-09-24 |
| IL208753A0 (en) | 2010-12-30 |
| AU2009244409A1 (en) | 2009-11-12 |
| KR20110015588A (ko) | 2011-02-16 |
| ZA201007649B (en) | 2012-04-25 |
| EP2280975B1 (en) | 2014-01-01 |
| MX2010011921A (es) | 2010-11-30 |
| TW200951135A (en) | 2009-12-16 |
| EA201001748A1 (ru) | 2011-06-30 |
| WO2009137454A1 (en) | 2009-11-12 |
| AR071684A1 (es) | 2010-07-07 |
| NZ588556A (en) | 2012-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7473688B2 (en) | Indolobenzazepine HCV NS5B inhibitors | |
| JP5232178B2 (ja) | Ｃ型肝炎の治療のための化合物 | |
| US7485633B2 (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
| JP5465670B2 (ja) | Ｃ型肝炎を治療するための化合物 | |
| JP5301473B2 (ja) | Ｃ型肝炎の治療のための化合物 | |
| CN101918410B (zh) | 与环丙基稠合的吲哚并苯并氮杂*hcv ns5b抑制剂 | |
| JP5343011B2 (ja) | Ｃ型肝炎の治療のための化合物 | |
| JP2010521483A (ja) | シクロプロピル縮合インドロベンゾアゼピンｈｃｖインヒビター | |
| CN102083834A (zh) | 用于治疗丙型肝炎的7H-吲哚并[2，1-a][2]苯并氮杂*-10-羧酸衍生物 | |
| WO2008111978A1 (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | |
| CN101443336B (zh) | 环丙基稠合的[吲哚]并[苯并氮杂*]hcv ns5b抑制剂 | |
| JP2012517468A (ja) | Ｃ型肝炎治療のための化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20110601 |